



# Multidisciplinary Respiratory Medicine



Official Journal of IRS Research Center  
Rivista ufficiale di Centro Studi SIP

## Editor-in-Chief

**C.M. Sanguinetti**

In PubMed  
Central  
Cite score 2020 **3.4**  
SJR value 2020 **0.720**  
SNIP 2020 **1.215**

- *A. Fathala, A. Aldurabi*  
**Frequency of computed tomography abnormalities in patients with chronic thromboembolic pulmonary hypertension: a comparative study between lung perfusion scan and computed tomography pulmonary angiography**
- *S.A.A. Mohamed, A. AbdelHafeez, E. Kamel, A. Rashad*  
**Utility of a modified distress thermometer in screening COVID-19 patients for psychological distress: a prospective Egyptian study**
- *I. Coloretti, S. Busani, E. Biagioni, S. Venturelli, E. Munari, M. Sita, L. Dall'Ara, M. Tosi, E. Clini, R. Tonelli, R. Fantini, C. Mussini, M. Meschiari, G. Guaraldi, A. Cossarizza, G. Alfano, M. Girardis, for the Modena COVID-19 Working Group (MoCo19)*  
**Effects of cytokine blocking agents on hospital mortality in patients admitted to ICU with acute respiratory distress syndrome by SARS-CoV-2 infection: retrospective cohort study**
- *T. Ikeda, A. Nakao, F. Igata, Y. Kinoshita, H. Kushima, T. Matsumoto, H. Ishii, K. Nabeshima, M. Fujita*  
**Feasibility, utility, and safety of transbronchial cryobiopsy for interstitial lung diseases in Japan**
- *V. Valentania, D.H.S. Somasetia, D. Hilmanto, D. Setiabudi, H.M.N. Nataprawira*  
**Modified PIRO (predisposition, insult, response, organ dysfunction) severity score as a predictor for mortality of children with pneumonia in Hasan Sadikin Hospital, Bandung, Indonesia**
- *N. Murgia, A.G. Corsico, G. D'Amato, C.N. Maesano, A. Tozzi, I. Annesi-Maesano*  
**Do gene-environment interactions play a role in COVID-19 distribution? The case of Alpha-1 Antitrypsin, air pollution and COVID-19**
- *F. Menzella, C. Galeone, G. Ghidoni, P. Ruggiero, S. Capobelli, A. Simonazzi, C. Catellani, C. Scelfo, F. Livrieri, N. Facciolongo*  
**Successful treatment with benralizumab in a patient with eosinophilic granulomatosis with polyangiitis refractory to mepolizumab**

Abstracted/Indexed in: PubMed, PubMed Central, Embase, ESCI, Academic Search, DOAJ, EBSCO, Google Scholar, OCLC, SCImago, Summon and SCOPUS



# Multidisciplinary Respiratory Medicine



Official Journal of IRS Research Center  
Rivista ufficiale di Centro Studi SIP

## AIMS AND SCOPE

*Multidisciplinary Respiratory Medicine* is a peer-reviewed, open access journal encompassing all aspects of respiratory medicine. It has a particular focus on interdisciplinary and translational research. *Multidisciplinary Respiratory Medicine* is published online at <http://www.mrmjournal.org>.

The journal aims to provide a forum for the publication and free access of high quality original scientific articles, reviews and position papers documenting clinical and experimental advances in respiratory medicine, and related fields.

Given the journals interdisciplinary character, the target readership is wider than respiratory medicine, embracing numerous related disciplines (allergology, immunology, internal medicine, geriatrics, infectious diseases, intensive care, etc) and health professionals.

## COPYRIGHT AND LICENSE AGREEMENT

All articles published on the online version by *Multidisciplinary Respiratory Medicine* are made freely and permanently accessible online immediately upon publication, without subscription charges or registration barriers at <http://www.mrmjournal.org>. Further information about open access can be found at <https://pagepress.org/index.php/pagepress/openaccess>.

Authors of articles published on the online version of the Journal are the copyright holders of their articles and have granted to any third party, in advance and in perpetuity, the right to use, reproduce or disseminate the article, according to the journal's copyright and license agreement (see <https://www.mrmjournal.org/mrm/copy> for more information).

## PRODUCTION ONLINE VERSION

PAGEPress Publications

Via A. Cavagna Sangiuliani

527100 Pavia, Italy

Tel.: +39-0382-464340

Fax: +39-0382-34872

[www.pagepress.org](http://www.pagepress.org)

e-mail: [info@pagepress.org](mailto:info@pagepress.org) or [support@pagepress.org](mailto:support@pagepress.org)

## PRODUCTION PRINT VERSION AND ADVERTISING

Novamedia Srl

Tel.: +39-345-5099724

e-mail: [editorialoffice1@novamediasrl.com](mailto:editorialoffice1@novamediasrl.com)

## EDITORIAL OFFICE

Lilia Giannini

Tel.: +39-345-5099724 - Fax: +39-0322-072069

e-mail: [lilia.giannini@novamediasrl.com](mailto:lilia.giannini@novamediasrl.com)

## MANAGING DIRECTOR – DIRETTORE RESPONSABILE

Claudio M. Sanguinetti, Rome, Italy

## SUBSCRIPTION INFORMATION

Annual subscription rate for the print version (3 issues plus eventual supplements) € 90.00.

For further information, contact Novamedia srl,  
tel. +39-345 5099724, [editorialoffice1@novamediasrl.com](mailto:editorialoffice1@novamediasrl.com)

ISSN 1828-695X

## INFORMATION TO THE READER

Notification in accordance to the General Data Protection Regulation (EU) 2016/679 (GDPR). Subscribers' information is utilized, also in electronic mode, for the purpose of journal delivery as required and for related activities. Data treatment is owned by Novamedia Srl, Viale Brianza 22, 20127 Milan, Italy. The categories of persons responsible for data treatment for the above purpose are those involved in the registration, modification, elaboration and printing of data, in the production and delivery of the journal, in the call centers, and in the administration and economic management. As at the General Data Protection Regulation (EU) 2016/679 (GDPR), it is possible to exercise one's right to consult, modify, update or cancel one's information by applying to Novamedia srl, at the above address, who, on request, will provide a list of the responsible persons.

## TYPESETTER

Madison, Milan, Italy

## PRINTER

La Terra Promessa Scs, Novara, Italy

Registered at the Court of Novara n. 120/05 on 11/11/05.

Distribution in Italy occurs according to the General Data Protection Regulation (EU) 2016/679 (GDPR).

## OWNERSHIP

Novamedia Srl, Viale Brianza 22, 20127 Milan, Italy





# Multidisciplinary Respiratory Medicine

## Editor-in-Chief

**Claudio M Sanguinetti** Quisisana Clinical Center, Rome, Italy

## Associate Editors

*Coordinator:*

**Stefano Nardini** Vittorio Veneto General Hospital, Vittorio Veneto, Italy

- **Nicolino Ambrosino** ICS Maugeri, Montescano, Italy
- **Isabella Annesi-Maesano** Institut National de la Santé et de la Recherche Médicale, Paris, France
- **Heinrich Becker** University of Heidelberg, Heidelberg, Germany
- **Roberto W. Dal Negro** National Centre for Respiratory Pharmacoeconomics & Pharmacoepidemiology, Verona, Italy
- **Günseli Kilinc** University of Istanbul, Istanbul, Turkey
- **Stefano Marinari** SS. Annunziata Hospital, Chieti, Italy
- **Carlo Mereu** Santa Corona Hospital, Pietra Ligure, Savona, Italy
- **Antonio Sanna** San Jacopo Hospital, Pistoia, Italy

## Editorial Board

*Coordinator:*

**Mario Polverino** High Specialty Regional Centre, Salerno, Italy

- **Marco Alifano** Paris Descartes University, Paris, France
- **Alvar Augusti** University of Barcelona, Barcelona, Spain
- **Giorgio Bertolotti** Scientific Institute of Tradate, Tradate, Italy
- **Surinder S Biring** King's College Hospital, London, UK
- **Pierre-Régis Burgel** Cochin Hospital, Paris, France
- **Walter G. Canonica** University of Genoa, Genoa, Italy
- **Stefano Carlone** San Giovanni-Addolorata General Hospital, Rome, Italy
- **Richard Casaburi** UCLA Medical Center, Los Angeles, USA
- **Lucio Casali** University of Perugia, Perugia, Italy
- **Ciro Casanova** University "La Laguna", Santa Cruz de Tenerife, Spain
- **Bartolome Celli** Brigham and Women's Hospital, Boston, USA
- **Alexander A Chuchalin** Russian Medical State University, Moscow, Russian Federation
- **Peter A. Cistulli** University of Sidney, Sidney, Australia
- **Bruno Crestani** Université de Paris, Inserm U1152, Paris, France
- **Claudia Crimi** AOU Vittorio Emanuele Hospital, Catania, Italy
- **Giacomo Cusumano** Vittorio Emanuele Hospital, Catania, Italy
- **Gennaro D'Amato** A. Cardarelli Hospital, Naples, Italy
- **Fernando De Benedetto** University of Chieti, Chieti, Italy
- **Juan Pablo de Torres Tajés** Clinica Universidad de Navarra, Pamplona, Spain
- **Mario Del Donno** University "Federico II", Naples, Italy
- **Peter Diczpinigaitis** Albert Einstein College of Medicine, New York, USA
- **Miguel Divo** Brigham and Women's Hospital, Boston, USA

- **Claudio F. Donner†** Mondo Medico Clinic, Borgomanero, Italy
- **Emmi Lorenzo** University of Florence, AOU Careggi, Florence, Italy
- **Andrew Farmer** University of Oxford, Oxford, UK
- **Alessandro Fois** University of Sassari, Sassari, Italy
- **Roger Goldstein** University of Toronto, Toronto, Canada
- **Stefano Guerra** University of Arizona, Tucson, USA
- **Peter Howard** University of Sheffield, Sheffield, UK
- **Arturo H. Huerta Garcia** Hospital Clinic de Barcelona, Barcelona, Spain
- **Marc Humbert** Université Paris-Sud, Paris, France
- **Ahmad Kantar** Pediatric Asthma and Cough Center, Ponte San Pietro, Italy
- **José M<sup>a</sup> Marin** University of Zaragoza, Zaragoza, Spain
- **Fernando J Martinez** Weill Cornell Medical College, New York, USA
- **Alyn H. Morice** University of Hull, Cottingham, UK
- **Margherita Neri** Renato Piatti Onlus, Varese, Italy
- **Luis VF Oliveira** University Center of Anápolis, Anápolis, Brazil
- **Fabio Pace** Bolognini Hospital, Seriate, Italy
- **Paolo Palange** Sapienza University, Rome, Italy
- **Martyn R Partridge** Imperial College London, UK
- **Riccardo Pela** C. e G. Mazzoni Hospital, Ascoli Piceno, Italy
- **Massimo Pistolesi** AOU Careggi, Florence, Italy
- **Eva Polverino** Hospital Universitari Vall d'Hebron, Barcelona, Spain
- **Francesca Polverino** University of Arizona, Tucson, USA
- **Stephen I Rennard** University of Nebraska, Omaha, USA
- **Josep Roca** Institut d'Investigacions Biomèdiques August Pi i Sunyer, Barcelona, Spain
- **Yogesh Saini** University of North Carolina, Chapel Hill, USA
- **Sundeep Salvi** Chest Research Foundation, Pune, India
- **Gianfranco Sevieri** Viareggio, Lucca, Italy
- **Joan B. Soriano** Universidad Autónoma de Madrid, Madrid, Spain
- **Samy Suissa** McGill University, Montreal, Canada
- **Martin Tobin** University of Chicago, Maywood, USA
- **Philip Tønnesen** Gentofte University Hospital, Copenhagen, Denmark
- **Domenico M. Toraldo** "V Fazzi" Hospital, Lecce, Italy
- **Hoi Nam Tse** Hong Kong Baptist Hospital, Hong Kong, China
- **Giovanni Viegi** National Research Council, Institute of Biomedicine and Molecular Immunology A. Monroy, Palermo, Italy
- **Jadwicha Wedzicha** University College London, London, UK
- **Robert West** University College, London, UK
- **Emiel FM Wouters** University Hospital Maastricht, Maastricht, Netherlands
- **Alessandro Zanasi** Italian Association for Cough Study (AIST), Bologna, Italy
- **Salah Zeineldine** American University of Beirut, Beirut, Lebanon
- **Richard Zuwallack** University of Connecticut, Hartford, USA

## Managing Editor

**Lilia Giannini** Editorial Office. Arona, Italy



## In memory of Dr. Claudio F. Donner

In 2010 in Viareggio during the “Corso Master in Medicina Respiratoria “ Dr. Claudio Donner (on the left) rewarded Marcello Lippi, coach of the Italian National Football Club, for his support in favor of the national campaign on COPD “SOS RESPIRO”.

Claudio F. Donner suddenly passed away on August 19 of this year. He was one of the most outstanding and skilled scientists in the field of respiratory medicine.

Born in Varese (Italy) in 1948, he graduated in medicine *cum laude* from Pavia University in 1972, achieved the specializations in Occupational Medicine, Physiokinotherapy, and Respiratory Medicine, and eventually attended for some months the Medical Research Institute directed by Prof. Gordon Cumming in England. From early Eighties and for many years further he was at the head of Pulmonary Division of Salvatore Maugery Foundation in Veruno (Novara, Italy). Author of numerous textbooks, at both national and international level, and of numerous original scientific papers mainly in respiratory medicine (more than 207 indexed in PubMed), he was charged with lectureship in several Italian universities. Member of the numerous Italian and International respiratory Societies, he held the position of Secretary General of European Respiratory Society (ERS) from 1998 to 2004 and President of Italian Association of Hospital Pneumologists (AIPO). In 2006, after the foundation of AIMAR (Italian Interdisciplinary Association for Research in Lung Disease), of which he was President

from 2006 to 2012 and since 2015 Honorary President, together with some colleagues, among whom the undersigned, he realized the publication and was Co-Editor up to 2016 of *Multidisciplinary Respiratory Medicine* (MRM), a journal with a particular focus on interdisciplinary research, open to the contribution of all scientists who for various reasons are interested in respiratory medicine. Since then, MRM made great strides and now it occupies a firm position in the international scenery of respiratory journals. On the whole, his interest for the scientific literature and the international research was huge and that's why he was always and up to his last days reviewer of several important scientific publications.

The above mentioned activities are only a few of the numerous achievements Claudio attained in his professional life, always without leaving out his beloved family.

The death of Claudio Donner is a heavy loss for the pneumology at international level and for me also the irrecoverable loss of a dear friend.

*Claudio M. Sanguinetti*  
Editor-in-Chief of *Multidisciplinary*  
*Respiratory Medicine*

---

## Original research articles

- Frequency of computed tomography abnormalities in patients with chronic thromboembolic pulmonary hypertension: a comparative study between lung perfusion scan and computed tomography pulmonary angiography** 5  
Ahmed Fathala, Alaa Aldurabi
- Utility of a modified distress thermometer in screening COVID-19 patients for psychological distress: a prospective Egyptian study** 11  
Sherif A.A. Mohamed, Azza AbdelHafeez, Ehab Kamel, Alaa Rashad
- Effects of cytokine blocking agents on hospital mortality in patients admitted to ICU with acute respiratory distress syndrome by SARS-CoV-2 infection: retrospective cohort study** 19  
Irene Coloretti, Stefano Busani, Emanuela Biagioni, Sophie Venturelli, Elena Munari, Marco Sita, Lorenzo Dall'Ara, Martina Tosi, Enrico Clini, Roberto Tonelli, Riccardo Fantini, Cristina Mussini, Marianna Meschiari, Giovanni Guaraldi, Andrea Cossarizza, Gaetano Alfano, Massimo Girardis, for the Modena COVID-19 Working Group (MoCo19)
- Feasibility, utility, and safety of transbronchial cryobiopsy for interstitial lung diseases in Japan** 26  
Takato Ikeda, Akira Nakao, Fumiyasu Igata, Yoshiaki Kinoshita, Hisako Kushima, Takemasa Matsumoto, Hiroshi Ishii, Kazuki Nabeshima, Masaki Fujita
- Modified PIRO (predisposition, insult, response, organ dysfunction) severity score as a predictor for mortality of children with pneumonia in Hasan Sadikin Hospital, Bandung, Indonesia** 30  
Vebri Valentania, Dadang H. Somasetia, Dany Hilmanto, Djatnika Setiabudi, Heda Melinda N. Nataprawira
- ## Short reports
- Do gene-environment interactions play a role in COVID-19 distribution? The case of Alpha-1 Antitrypsin, air pollution and COVID-19** 37  
Nicola Murgia, Angelo Guido Corsico, Gennaro D'Amato, Cara Nichole Maesano, Arturo Tozzi, Isabella Annesi-Maesano
- Identification of patients with COVID-19 who are optimal for methylprednisolone pulse therapy** 41  
Shosei Ro, Naoki Nishimura, Ryosuke Imai, Yutaka Tomishima, Clara So, Manabu Murakami, Kohei Okafuji, Atsushi Kitamura, Torahiko Jinta, Tomohide Tamura

**Letter to the Editor**

- Worsening of gas exchange parameters at high FiO<sub>2</sub> in COVID-19: misleading or informative?** 46  
Federico Raimondi, Luca Novelli, Gianmariano Marchesi, Fabrizio Fabretti, Lorenzo Grazioli, Ivano Riva, Chiara Allegri, Roberta Biza, Chiara Galimberti, Ferdinando Luca Lorini, Fabiano Di Marco

**Case report**

- Successful treatment with benralizumab in a patient with eosinophilic granulomatosis** 50  
Francesco Menzella, Carla Galeone, Giulia Ghidoni, Patrizia Ruggiero, Silvia Capobelli, Anna Simonazzi, Chiara Catellani, Chiara Scelfo, Francesco Livrieri, Nicola Facciolongo

**Caso clinico**

- Aspergillosi polmonare invasiva con disseminazione cerebrale fatale in un paziente con polmonite da COVID-19** I  
Sara Dal Farra, Monica Giordanengo, Paolo Baderna, Maria Rosaria La Ghezza, Nicola Launaro

**Rubriche**

- L'angolo della Cultura (non solo Medicina...)**  
La grande beffa del Louvre V  
Francesco Iodice
- Meeting calendar** IX

## Meeting Calendar

| WHEN              | WHERE                  | WHAT  | WHO TO CONTACT   |
|-------------------|------------------------|---|--|
| <b>2021</b>       |                        |   |  |
| September<br>5-8  | Barcelona<br>(Spain)   | ERS International Congress 2021 – virtual event   | <a href="https://erscongress.org/">https://erscongress.org/</a>  |
| @ October<br>7-9  | Catanzaro<br>(Italy)   | V Corso Nazionale: “OSAS, la gestione multidisciplinare e multiprofessionale in età adulta”   | <a href="mailto:info@samacongressi.it">info@samacongressi.it</a><br><a href="http://www.samacongressi.it">www.samacongressi.it</a> |
| November<br>4-5   | Lisbon<br>(Portugal)   | Research seminar: “Innovative 3D models for understanding mechanisms underlying lung diseases: powerful tools for translational research” | <a href="https://erscongress.org/">https://erscongress.org/</a>  |
| November<br>17-18 | Brussels<br>and online | European Cancer Summit 2021   | <a href="https://www.europecancer.org/summit#overview">https://www.europecancer.org/summit#overview</a>                            |
| November<br>20-21 | Kyoto<br>(Japan)       | APSR 2020 – The 25 <sup>th</sup> Congress of the Asian Pacific Society of Respirology – hybrid event                                      | <a href="mailto:info@apsr2020.jp">info@apsr2020.jp</a>   |
| November<br>25-27 | Budapest<br>(Hungary)  | Course: “Lung transplantation: Sharing experience across Europe”  | <a href="https://erscongress.org/">https://erscongress.org/</a>  |
| December<br>4-7   | Salzburg<br>(Austria)  | 8 <sup>th</sup> ESWI Influenza Conference: “Hot Topics on Influenza RSV and COVID-19”   | <a href="https://www.eswiconference.org/">https://www.eswiconference.org/</a>  |

@ = evento Centro Studi SIP

# BORNILENE

XIBORNOLO

## RIASSUNTO DELLE CARATTERISTICHE DEL PRODOTTO

100/07

### 1. DENOMINAZIONE DEL MEDICINALE

BORNILENE 30 mg/ml sospensione spray per mucosa orale.

### 2. COMPOSIZIONE QUALITATIVA e QUANTITATIVA

100 ml di sospensione contengono 3 g di Xibornolo.

Eccipienti con effetti noti: etanolo e olio di ricino.

Per l'elenco completo degli eccipienti, vedere paragrafo 6.1.

### 3. FORMA FARMACEUTICA

Sospensione spray per mucosa orale.

### 4. INFORMAZIONI CLINICHE

#### 4.1 Indicazioni terapeutiche

Coadiuvante nel trattamento delle infezioni e degli stati infiammatori della sfera faringea causate da germi sensibili allo xibornolo (faringiti, laringiti, rinofaringiti, tonsilliti acute e croniche). Igiene locale pre e post operatoria. Adjuvante e antisettico nella pratica dentistica.

#### 4.2 Posologia e modo di somministrazione

##### Posologia

Da 4 a 6 nebulizzazioni faringee al giorno ad intervalli regolari.

##### Modo di somministrazione

Sollevare il beccuccio. Dirigere il getto verso l'area interessata, mantenendo il flacone verticale. Agitare bene prima di ogni erogazione. Per il primo impiego premere tre volte per innescare la pompa ad alta precisione.

#### 4.3 Controindicazioni

Ipersensibilità al principio attivo o ad uno qualsiasi degli eccipienti elencati al paragrafo 6.1 o a sostanze strettamente correlate dal punto di vista chimico. Controindicato in gravidanza e in allattamento (vedere paragrafo 4.6).

#### 4.4 Avvertenze speciali e precauzioni d'impiego

Evitare l'impiego in soggetti affetti da asma allergica.

#### 4.5 Interazioni con altri medicinali e altre forme d'interazione

Nessuna interazione è stata finora riscontrata.

#### 4.6 Fertilità, gravidanza e allattamento

Sebbene gli studi sperimentali di tossicità non abbiano evidenziato attività teratogena né tossicità fetale, a scopo precauzionale, è preferibile non utilizzare il prodotto in gravidanza e durante l'allattamento.

#### 4.7 Effetti sulle capacità di guidare veicoli e sull'uso di macchinari

BORNILENE non influenza la capacità di guidare veicoli e usare macchinari.

#### 4.8 Effetti indesiderati

Non sono stati riportati effetti indesiderati.

##### Segnalazione delle reazioni avverse sospette

La segnalazione delle reazioni avverse sospette che si verificano dopo l'autorizzazione del medicinale è importante, in quanto permette un monitoraggio continuo del rapporto beneficio/rischio del medicinale. Agli operatori sanitari è richiesto di segnalare qualsiasi reazione avversa sospetta tramite il sistema nazionale di segnalazione all'indirizzo [www.agenziafarmaco.gov.it/content/come-segnalare-una-sospetta-reazione-avversa](http://www.agenziafarmaco.gov.it/content/come-segnalare-una-sospetta-reazione-avversa).

#### 4.9 Sovradosaggio

In letteratura non sono riportati casi di sovradosaggio.

### 5. PROPRIETA' FARMACOLOGICHE

#### 5.1 Proprietà farmacodinamiche

Categoria farmaco-terapeutica: preparati per il cavo faringeo, antisettici, vari.

Codice ATC: R02AA20

Il principio attivo del Bornilene è lo xibornolo (6-isobornil-3,4 xilenolo), un derivato fenolico del bornano dotato di attività batteriostatica e battericida sulla maggior parte dei germi gram-positivi e sull'*Haemophilus influenzae*, nonché di azione virucida di contatto e di azione fungistatica. Il clorobutanolo è presente nella formulazione quale agente antalgico topico.

### 6. INFORMAZIONI FARMACEUTICHE

#### 6.1 Elenco degli Eccipienti

Glicerolo, etanolo 96% v/v, cellulosa microcristallina e carmellosa sodica, 30% simeticone emulsione, mentolo clatrato, ammonio glicirrinato, clorobutanolo emidrato, saccarina sodica, citrale clatrato, silice colloidale anidra, olio di ricino polietossilato, potassio sorbato, acqua depurata.

#### 6.2 Incompatibilità

Nessuna finora nota.

#### 6.3 Periodo di Validità

2 anni: in confezionamento integro, correttamente conservato. Dopo prima apertura del flacone: 3 mesi.

#### 6.4 Precauzioni particolari per la conservazione

Questo medicinale non richiede alcuna condizione particolare di conservazione.

#### 6.5 Natura e contenuto del contenitore

Flacone in vetro ambrato contenente 30 ml di prodotto dotato di valvola metrica predosata e di beccuccio erogatore e cappello protettivo.

#### 6.6 Precauzioni particolari per lo smaltimento

Nessuna istruzione particolare.

### 7. TITOLARE DELL'AUTORIZZAZIONE ALL'IMMISSIONE IN COMMERCIO

ABIOTEN PHARMA S.p.A. - Via Meucci, 36 - Ospedaletto - Pisa

### 8. NUMERO DELL'AUTORIZZAZIONE ALL'IMMISSIONE IN COMMERCIO

BORNILENE 30 mg/ml sospensione spray per mucosa orale  
flacone nebulizzatore da 30 ml  
AIC n. 026642052

### 9. DATA DI PRIMA AUTORIZZAZIONE/RINNOVO DELL'AUTORIZZAZIONE

Data della prima autorizzazione: 14 novembre 1997

Data del rinnovo più recente: 14 novembre 2007

### 10. DATA DI REVISIONE DEL TESTO

Ottobre 2020

30 mg/ml sospensione spray per mucosa orale  
flacone 30 ml  
Euro 14,80  
Classe C - RR



# OSAS: la gestione multidisciplinare e multiprofessionale in età adulta

V Corso  
Nazionale

**WEBINAR**  
25 settembre 2021  
1 ottobre 2021

**IN PRESENZA**  
7-9 ottobre 2021  
**Catanzaro**  
*Hotel Perla del Porto*

## Responsabile Scientifico

Antonio Sanna

## Comitato Scientifico

Marcello Bosi

Loreta Di Michele

Donato Lacedonia

Luigi Marino

Antonio Sanna

Maurizio Domenico Toraldo

## Provider

Centro Studi SIP/IRS – Provider n. 172  
Via San Gregorio, 12 - 20124 Milano MI

## Segreteria Organizzativa

**S.A.M.A.**  
Service & Congress

Via Provinciale 8/A Mili S. Marco  
98132 Messina

Tel/Fax: + 39 090 68 11 318

info@samacongressi.it

www.samacongressi.it

## Figure professionali

– **Medici** (*Discipline: malattie apparato respiratorio, anestesia e rianimazione, otorinolaringoiatria, neurologia, medicina del lavoro, medicina legale, cardiologia, medicina interna, diabetologia, endocrinologia, chirurgia maxillo facciale, farmacologia clinica, medicina generale*)

– **Medici in formazione specialistica** (*Discipline: malattie dell'apparato respiratorio*)

– **Odontoiatri** (*Discipline: odontoiatria*)

– **Tecnici di neurofisiopatologia** (*Discipline: tecniche di neurofisiopatologia*)

– **Fisioterapisti** (*Discipline: fisioterapia*)

– **Infermieri** (*Discipline: infermiere*)

## Obiettivi Formativi

– fornire gli strumenti culturali da utilizzare per la creazione di una rete di conoscenze ed esperienze da condividere a vantaggio della persona malata di OSAS.

– per i medici specialisti e in formazione specialistica in malattie dell'apparato respiratorio (ultimi 2 anni) certificare la qualifica di **“Medico esperto nella gestione del soggetto OSAS”**

– per i MMG, odontoiatri, tecnici di neurofisiopatologia, fisioterapisti e infermieri rilasciare **“Attestato di Alta formazione sull'OSAS”**

Tali titoli formativi sono rilasciati dal Centro Studi SIP/IRS, Ente di Ricerca riconosciuto dalla Presidenza del Consiglio dei Ministri (D.P.C.M. – 4 febbraio 2015).

# NUOVO **BORNILENE**

XIBORNOLO

**S**barramento antinfettivo  
di prima linea  
della sfera faringea<sup>1,2</sup>

Euro 14,80  
Classe C - RR



*Cambia veste rimanendo se stesso*<sup>1</sup>

**Coadiuvante nel trattamento delle infezioni** e degli stati infiammatori della sfera faringea causate da germi sensibili allo xibornolo (faringiti, laringiti, rinofaringiti, tonsilliti acute e croniche). **Igiene locale** pre e post operatoria. Aduvante e **antisettico** nella pratica dentistica.<sup>1</sup>

